Molecular Partners AG
Molecular Partners AG develops DARPin therapeutics for cancer, including radiopharmaceuticals for targeted alpha therapy and immune cell engagers.
10-QNov 16Latest SEC filing
Oct 29Latest story
Molecular Partners AG develops DARPin therapeutics for cancer, including radiopharmaceuticals for targeted alpha therapy and immune cell engagers.
October 2026
August 2026
July 2026